PMS-GLYBURIDE TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

GLYBURIDE

Доступна с:

PHARMASCIENCE INC

код АТС:

A10BB01

ИНН (Международная Имя):

GLIBENCLAMIDE

дозировка:

5MG

Фармацевтическая форма:

TABLET

состав:

GLYBURIDE 5MG

Администрация маршрут:

ORAL

Штук в упаковке:

30/100/300/500

Тип рецепта:

Prescription

Терапевтические области:

SULFONYLUREAS

Обзор продуктов:

Active ingredient group (AIG) number: 0108708001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

1997-10-17

Характеристики продукта

PRODUCT MONOGRAPH
PR
PMS-GLYBURIDE
Glyburide Tablets
5 mg
House Standard
Oral Hypoglycaemic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
July 3, 2012
Submission Control No.: 156675
_ _
_Product Monograph pms-GLYBURIDE _
_Page 2 of 31_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................20
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARMACOLOGY
................................................................